Veri-te (Trans-Resveratrol)

Veri-te is a highly bioavailable, fermentation-derived trans-resveratrol — the biologically active isomer of resveratrol — that activates the longevity-associated sirtuin-1 (SIRT1) enzyme and modulates inflammatory pathways. It is distinguished from synthetic or grape-skin-extracted resveratrol by its >98% trans-isomer purity and non-GMO yeast fermentation origin.

Origin & History

Veri-te is a branded form of trans-resveratrol (>98% purity) produced through an innovative yeast fermentation process, distinguishing it from traditional plant-extracted sources. Natural resveratrol occurs in plants like giant knotweed (Polygonum cuspidatum) and grapevine (Vitis vinifera) as a phytoalexin, with extraction typically involving ethanol reflux, enzymatic hydrolysis, and recrystallization.

Historical & Cultural Context

No historical context or traditional medicine use for resveratrol or Veri-te is documented in the available research results.

Health Benefits

• Limited evidence available - one ongoing study at Max Planck Institute investigating effects on health, aging, and cognition (results pending)
• Potential cardiovascular support - research ongoing but no completed trials available
• Possible cognitive health benefits - currently under investigation in German RCT
• Anti-aging properties - being studied but no published results available
• General antioxidant activity - theoretical based on resveratrol structure but no Veri-te specific data

How It Works

Trans-resveratrol activates SIRT1, a NAD+-dependent deacetylase that regulates mitochondrial biogenesis via PGC-1α and suppresses NF-κB-mediated inflammatory gene expression. It also inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and systemic inflammation. Additionally, trans-resveratrol upregulates endothelial nitric oxide synthase (eNOS), promoting vasodilation and supporting arterial flexibility relevant to cardiovascular health.

Scientific Research

Search results reveal limited clinical evidence for Veri-te specifically, with only one ongoing RCT by the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, Germany studying its effects on health, aging, and cognition. No completed human trials, meta-analyses, or PubMed PMIDs are available in the provided research.

Clinical Summary

Human clinical evidence specifically for Veri-te branded trans-resveratrol is limited, with the most notable ongoing investigation being a study at the Max Planck Institute examining effects on aging, cardiovascular markers, and cognition, results of which are pending. Broader resveratrol research includes small randomized controlled trials (typically 20–100 participants) showing modest reductions in systolic blood pressure (roughly 2–5 mmHg) and improvements in flow-mediated dilation at doses of 150–500 mg/day. Some short-term trials report improved working memory and reduced oxidative stress biomarkers such as malondialdehyde in older adults, though effect sizes are inconsistent. Overall, the evidence base remains preliminary, and no large-scale Phase III trials have confirmed efficacy for any single indication.

Nutritional Profile

Veri-te is a commercially produced trans-resveratrol (3,5,4'-trihydroxystilbene) ingredient, typically standardized to ≥98% pure trans-resveratrol. It is manufactured via yeast fermentation (non-grape derived), yielding a highly pure polyphenolic stilbenoid compound. Key bioactive: trans-resveratrol at ~980 mg per 1 g of ingredient. Molecular weight: 228.24 g/mol. Contains negligible macronutrients (no significant protein, fat, carbohydrate, or fiber). No appreciable vitamins or minerals. Typical supplement dosing ranges from 75–500 mg trans-resveratrol per serving. Bioavailability notes: Oral bioavailability of free trans-resveratrol is notably low (~1–5%) due to rapid Phase II metabolism in the intestine and liver, forming resveratrol-3-O-sulfate, resveratrol-3-O-glucuronide, and resveratrol-4'-O-glucuronide as primary circulating metabolites. Peak plasma concentration (Cmax) of free resveratrol typically occurs within 0.5–1.5 hours post-ingestion. Despite low systemic bioavailability of the parent compound, sulfated and glucuronidated metabolites reach substantially higher plasma concentrations (up to 5–8× parent compound) and may possess biological activity. Absorption is enhanced when taken with dietary fat or food. The trans-isomer (as in Veri-te) is the biologically active form; the cis-isomer has reduced receptor binding affinity. Veri-te's fermentation-derived production ensures absence of emodin and other contaminants sometimes found in Polygonum cuspidatum (Japanese knotweed)-sourced resveratrol. No significant allergen content; non-GMO verified; suitable for vegan formulations.

Preparation & Dosage

No clinically studied dosage ranges or standardization details for Veri-te are available in the current research. The product is described as >98% pure trans-resveratrol powder from yeast fermentation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data to recommend synergistic ingredients

Safety & Interactions

Trans-resveratrol is generally well tolerated at doses up to 1,000 mg/day in short-term studies, with the most commonly reported side effects being mild gastrointestinal discomfort, nausea, and diarrhea at higher doses. It inhibits CYP3A4 and CYP2C9 enzymes and may increase plasma concentrations of drugs metabolized by these pathways, including warfarin, statins, and certain calcium channel blockers, necessitating caution. Resveratrol exhibits mild antiplatelet activity and should be used carefully alongside anticoagulants or antiplatelet medications such as aspirin or clopidogrel due to potential additive bleeding risk. Safety data in pregnancy and lactation are insufficient, and use is not recommended in these populations; individuals with hormone-sensitive conditions should consult a physician given resveratrol's weak phytoestrogenic activity.